Canada markets open in 3 hours 21 minutes

Aurora Cannabis Inc. (ACB.TO)

Toronto - Toronto Real Time Price. Currency in CAD
Add to watchlist
6.97-0.06 (-0.85%)
At close: 04:00PM EDT
Full screen
Previous Close7.03
Open6.91
Bid6.94 x 0
Ask6.95 x 0
Day's Range6.83 - 7.18
52 Week Range3.84 - 15.50
Volume752,325
Avg. Volume2,157,938
Market Cap380.2M
Beta (5Y Monthly)2.59
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • PR Newswire

    Aurora Cannabis Files Full Year Results and Announces Fiscal 2024 Fourth Quarter

    Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ: ACB) (TSX: ACB), a leading Canada-based global medical cannabis company, today announced its financial and operational results for the fourth quarter and fiscal year 2024. As the fiscal year 2023 consisted of three quarters, the year-over-year comparison quarter for Q4 2024 ending March 31, 2024 is Q3 2023 ending March 31, 2023.

  • CNW Group

    Aurora Cannabis to Host Fourth Quarter and Fiscal Year 2024 Investor Conference Call and File Related Year End Information

    Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ: ACB) (TSX: ACB), a leading Canada-based global medical cannabis company, announced today that it has scheduled a conference call to discuss the results for its fourth quarter and fiscal year 2024 on Thursday, June 20, 2024 at 8:00 a.m. Eastern Time | 6:00 a.m. Mountain Time. The Company will report its financial results for the fourth quarter fiscal year 2024 before the opening of markets that same day.

  • CNW Group

    Aurora Unveils Premium Resin Cartridges in Australia

    Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB) – the Canadian based leading global medical cannabis company, in conjunction with MedReleaf Australia, is excited to announce the launch of its premium 1.2g resin cartridges in Australia. This expansion marks a significant step in Aurora's mission to provide high-quality products to patients worldwide. Now available for doctors to prescribe to patients in Australia, Aurora's new resign cartridges, developed and manufactured at the company's EU-GMP an